Mechanism
Shelterin complex
Reference definition for a telomere-biology node.
Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.
Definition
Category: Protective protein cap
Also known as: telosome, TRF1, TRF2, POT1, TIN2, TPP1, RAP1
Shelterin is the six-protein complex (TRF1, TRF2, POT1, TIN2, TPP1, RAP1) that binds telomeric DNA, shapes the protective cap, and controls access of telomerase and the DNA-repair machinery to the chromosome end. It is what makes a telomere function as a cap rather than as a broken end.
Key points
- TRF1 and TRF2 bind the double-stranded telomeric repeats; POT1 binds the single-stranded overhang — together they suppress the DNA-damage response at the end.
- Shelterin both protects the end and regulates telomere length by gating telomerase access, so it is central to how length is maintained.
- Mutations in shelterin components (e.g. POT1) are linked to certain familial cancers, another thread in the telomere–cancer relationship.
Sourcing
Standard shelterin reviews (de Lange, 'Shelterin'). Review-level description.
Reference synthesis (tier 4); verification: review_level_2026-07-12.